Hematology

A study reveals that APOE e4 carriers with atrial fibrillation on Eliquis face increased intracranial hemorrhage risk, highlighting critical genetic implications.

Explore key FDA decisions in Q4 2025, impacting treatments for atopic dermatitis, chronic rhinosinusitis, and rare diseases.

Denecimig may offer a prophylaxis bleed treatment option for a range of patients across dosing frequencies, age groups, and condition severity.

This Sickle Cell Awareness Month, HCPLive draws attention to recent advancements made in SCD treatment and how much still needs to be done to address it.

An audio recap of the top 5 stories in healthcare news from the week of 08/31-9/5.

Stay updated with the latest healthcare breakthroughs, including FDA news and phase 3 clinical trial data, in this week's essential news roundup.

FDA expands Vonvendi approval for all von Willebrand disease types, enhancing treatment options for adults and children with this rare condition.

Agios announces a 3-month extension for mitapivat's FDA review.

An audio recap of the top 5 stories in healthcare news from the week of 08/24-08/30.

Stay updated with the latest healthcare breakthroughs, including FDA news, vaccine guidelines, and orforglipron data, in this week's essential news roundup.

If approved, the investigative therapy could provide a frontline treatment for patients with SAA who do not have matched sibling donors for cell transplantation.

Stay updated with the latest healthcare breakthroughs, including FDA news and new guidelines, in this week's essential news roundup.

This new monoclonal antibody has achieved a statistically significant improvement in time to treatment failure, indicating a potential to revolutionize ITP.

The FDA approved generic versions of Venofer (iron sucrose) injection from Viatris Inc and Amphastar Pharmaceuticals.

This FDA News Month in Review provides a round-up of regulatory decisions from July 2025.

The therapy was originally approved under the name Alhemo for people with hemophilia ages 12 and up without inhibitors.

An analysis of data from the LUNA 3 trial indicated the comparative safety and clinical significance of the IWG criteria versus the standard platelet count threshold.

A review of data from an ongoing phase 3 trial indicates the potential for a generalized, prespecified fitusiran treatment for hemophilia A and B.

Kuter describes several studies investigating aspects of rilzabrutinib which were presented at the ISTH 2025 Congress.

Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in hematology.

A review of the 16 novel drugs approved by the US Food and Drug Administration during the first half of 2025, with links to coverage from MJH Life Sciences publications.

A relatively quiet quarter for hematology, punctuated by both successes and failures in clinical trials and a handful of Orphan Drug and Fast Track designations.

The FDA distributed several designations and many trials successfully met their endpoints during an eventful June for hematology.

Parent company Novo Nordisk has announced intentions to submit the treatment for approval later in 2025.

Data from the Phase 1/2 BEACON trial indicate the efficacy and safety of this investigative 1-time therapy, particularly in decreasing blood cell sickling.